Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated assessment statements are directly supported by the provided FDA label excerpts (Sections 5.2 and 5.3 for respiratory depression and CNS-depressant/benzodiazepine risks, and Sections 5.4 and 5.6 for neonates/children). No contradictions or unsupported safety claims were identified.
Category Scores
Accurate Statements
Serious, life-threatening, or fatal respiratory depression has been reported with opioids/tramadol ER, and may lead to respiratory arrest and death.
Section 5.2: “Serious, life-threatening, or fatal respiratory depression… may lead to respiratory arrest and death.”
The risk of respiratory depression is greatest during initiation of therapy or following a dosage increase.
Section 5.2: “the risk is greatest during the initiation of therapy or following a dosage increase.”
Concomitant use with benzodiazepines and/or other CNS depressants (including alcohol) may result in profound sedation, respiratory depression, coma, and death.
Section 5.3: “Profound sedation, respiratory depression, coma, and death may result…” and includes “including alcohol.”
Opioids increase risk of sleep-related breathing disorders such as central sleep apnea (CSA), dose-dependently.
Section 5.2: “Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA)… increases the risk… in a dose-dependent fashion.”
Neonatal opioid withdrawal syndrome may be life-threatening if not recognized and treated.
Section 5.4: “may be life-threatening if not recognized and treated…”
Life-threatening respiratory depression and death have occurred in children treated with tramadol, with pediatric contraindication/avoidance guidance.
Section 5.6: “Life-threatening respiratory depression and death have occurred in children…” plus contraindications/avoidance statements.
Unsupported Statements
None identified as making additional claims beyond what is explicitly supported in the cited label excerpts.
All safety-risk subcomponents referenced correspond to explicit wording in Sections 5.2/5.3/5.4/5.6 provided.
Contradictions
Important Omissions
No explicit mention of the dosage limit (e.g., not exceeding 300 mg/day) or specific administration instructions (swallow whole, oral once daily) in the AI response.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The evaluated AI content is limited to safety warning characterization (respiratory depression, CNS depressant/benzodiazepine co-use, neonates/children). These claims are directly supported by the provided label excerpts and do not introduce contradictory or unsupported risk statements.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Minor category-level partialness due to lack of specific dosage/administration limit details (not required to support the particular respiratory-depression interaction and life-threatening risk claims).
Suggested Improvement
If discussing overall safety comprehensively, also reference relevant dosage/administration limit and tampering constraints explicitly stated in Section 2 (e.g., max daily dose and swallowing whole) where applicable.